Recruitment

Recruitment Status
Completed

Inclusion Criterias

A1c less than or equal to 9%
Subjects diagnosed with Type 2 Diabetes mellitus;
Body mass index 25 to 40 kg/m2;
...
A1c less than or equal to 9%
Subjects diagnosed with Type 2 Diabetes mellitus;
Body mass index 25 to 40 kg/m2;
Subjects currently on oral agents or insulin;
Male or female subjects, aged 18-75 years;
Subjects able to comply with study procedures and sign informed consent

Exclusion Criterias

Subjects with diabetes mellitus treated with very high dose of sulfonylureas (glyburide>20 mg/day, , glimepiride >8 mg per day, and glipizide >20 mg per day) α-glucosidase inhibitors (acarbose ), or meglitinides (repaglinide >6 mg per day)), ;
Subject with gastrointestinal disease that may interfere with absorption of the investigational products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
Use of acetaminophen-containing products
...
Subjects with diabetes mellitus treated with very high dose of sulfonylureas (glyburide>20 mg/day, , glimepiride >8 mg per day, and glipizide >20 mg per day) α-glucosidase inhibitors (acarbose ), or meglitinides (repaglinide >6 mg per day)), ;
Subject with gastrointestinal disease that may interfere with absorption of the investigational products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
Use of acetaminophen-containing products
Medication (other than diabetes medications or insulin) or dietary supplement known to affect glucose or galactose metabolism
Lactose or galactose intolerance
Food allergy or severe food intolerance
History of eating disorder
Pregnant or lactating female
Subject has received any investigational agent within 30 days prior to the first dose of investigational product

Summary

Conditions
Type 2 Diabetes Treated With Insulin
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

In this study, the investigators seek to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans. Continuous glucose monitors (CGM) are minimally invasive devices that measure glucose levels in inters...

In this study, the investigators seek to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans. Continuous glucose monitors (CGM) are minimally invasive devices that measure glucose levels in interstitial fluid. A small wire is inserted subcutaneously which transmits the ambient subcutaneous glucose concentration every 5 minutes to a wireless recorder. In usual use, the patient can see these data and graph the previous 1, 3 or 9 hours to identify trends or look back over time (ie over night). In our study, the patient will be blinded to the data so as not to confound results, as it has been noted in another study that patient's blood sugar control was better when they were able to see CGM results and modified their diet. CGM's have been shown to have clinical accuracies of 95.5-98.9% and have been used in clinical trials and found to be safe. Having the patient do a finger-stick glucose intermittently during the time they are wearing the CGM improves accuracy.

Inclusion Criterias

A1c less than or equal to 9%
Subjects diagnosed with Type 2 Diabetes mellitus;
Body mass index 25 to 40 kg/m2;
...
A1c less than or equal to 9%
Subjects diagnosed with Type 2 Diabetes mellitus;
Body mass index 25 to 40 kg/m2;
Subjects currently on oral agents or insulin;
Male or female subjects, aged 18-75 years;
Subjects able to comply with study procedures and sign informed consent

Exclusion Criterias

Subjects with diabetes mellitus treated with very high dose of sulfonylureas (glyburide>20 mg/day, , glimepiride >8 mg per day, and glipizide >20 mg per day) α-glucosidase inhibitors (acarbose ), or meglitinides (repaglinide >6 mg per day)), ;
Subject with gastrointestinal disease that may interfere with absorption of the investigational products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
Use of acetaminophen-containing products
...
Subjects with diabetes mellitus treated with very high dose of sulfonylureas (glyburide>20 mg/day, , glimepiride >8 mg per day, and glipizide >20 mg per day) α-glucosidase inhibitors (acarbose ), or meglitinides (repaglinide >6 mg per day)), ;
Subject with gastrointestinal disease that may interfere with absorption of the investigational products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
Use of acetaminophen-containing products
Medication (other than diabetes medications or insulin) or dietary supplement known to affect glucose or galactose metabolism
Lactose or galactose intolerance
Food allergy or severe food intolerance
History of eating disorder
Pregnant or lactating female
Subject has received any investigational agent within 30 days prior to the first dose of investigational product

Locations

Dartmouth, New Hampshire, 03755
Dartmouth, New Hampshire, 03755

Tracking Information

NCT #
NCT02060916
Collaborators
Not Provided
Investigators
  • Principal Investigator: Laura E Trask, MD Dartmouth-Hitchcock Medical Center
  • Laura E Trask, MD Dartmouth-Hitchcock Medical Center